Literature DB >> 8462026

Severe 5-fluorouracil toxicity in a patient with decreased dihydropyrimidine dehydrogenase activity.

A P Lyss, R C Lilenbaum, B E Harris, R B Diasio.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8462026     DOI： 10.3109/07357909309024846

Source DB:  PubMed          Journal:  Cancer Invest        ISSN： 0735-7907            Impact factor:   2.176


× No keyword cloud information.
  16 in total

Review 1.  The role of pharmacogenetics in cancer therapeutics.

Authors:  Wei Peng Yong; Federico Innocenti; Mark J Ratain
Journal:  Br J Clin Pharmacol       Date:  2006-07       Impact factor: 4.335

2.  Reexamining a proposal: thymidylate synthase 5'-untranslated region as a regulator of translation efficiency.

Authors:  Soma Ghosh; Jordan M Winter; Kalpesh Patel; Scott E Kern
Journal:  Cancer Biol Ther       Date:  2011-10-15       Impact factor: 4.742

3.  Physiologically based pharmacokinetic modelling of the three-step metabolism of pyrimidine using C-uracil as an in vivo probe.

Authors:  Suminobu Ito; Takeshi Kawamura; Makoto Inada; Yoshiharu Inoue; Yukihiro Hirao; Toshihisa Koga; Jun-ichi Kunizaki; Takefumi Shimizu; Hitoshi Sato
Journal:  Br J Clin Pharmacol       Date:  2005-12       Impact factor: 4.335

Review 4.  Pharmacogenetics: a tool for individualizing antineoplastic therapy.

Authors:  F Innocenti; L Iyer; M J Ratain
Journal:  Clin Pharmacokinet       Date:  2000-11       Impact factor: 6.447

Review 5.  How may anticancer chemotherapy with fluorouracil be individualised?

Authors:  Su-arpa Ploylearmsaeng; Uwe Fuhr; Alexander Jetter
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

6.  Genotype-phenotype correlations in 5-fluorouracil metabolism: a candidate DPYD haplotype to improve toxicity prediction.

Authors:  G Gentile; A Botticelli; L Lionetto; F Mazzuca; M Simmaco; P Marchetti; M Borro
Journal:  Pharmacogenomics J       Date:  2015-07-28       Impact factor: 3.550

Review 7.  Molecular markers in colorectal cancer: genetic bases for a customised treatment.

Authors:  E Casado; J De Castro; C Belda-Iniesta; P Cejas; J Feliu; M Sereno; M González-Barón
Journal:  Clin Transl Oncol       Date:  2007-09       Impact factor: 3.405

8.  Management of colorectal cancer patients after resection of liver metastases: can we offer a tailored treatment?

Authors:  Miriam López-Gómez; Paloma Cejas; María Merino; David Fernández-Luengas; Enrique Casado; Jaime Feliu
Journal:  Clin Transl Oncol       Date:  2012-08-22       Impact factor: 3.405

Review 9.  Evaluating the drug-target relationship between thymidylate synthase expression and tumor response to 5-fluorouracil. Is it time to move forward?

Authors:  Shayna L Showalter; Timothy N Showalter; Agnes Witkiewicz; Robert Havens; Eugene P Kennedy; Tomas Hucl; Scott E Kern; Charles J Yeo; Jonathan R Brody
Journal:  Cancer Biol Ther       Date:  2008-04-21       Impact factor: 4.742

10.  Limits to thymidylate synthase and TP53 genes as predictive determinants for fluoropyrimidine sensitivity and further evidence for RNA-based toxicity as a major influence.

Authors:  Jonathan R Brody; Tomas Hucl; Christina L Costantino; James R Eshleman; Eike Gallmeier; Heng Zhu; Michiel S van der Heijden; Jordan M Winter; Agnieszka K Wikiewicz; Charles J Yeo; Scott E Kern
Journal:  Cancer Res       Date:  2009-01-20       Impact factor: 12.701
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.